Beam Therapeutics (BEAM) Short Interest Ratio & Short Volume

Short interest is the volume of Beam Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 13,130,000 shares of BEAM short. Learn More on Beam Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BEAM shares currently have a short interest ratio of 16.0. Learn More on Beam Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Beam Therapeutics: Walleye Capital LLC, Walleye Trading LLC, Citadel Advisors LLC, Citigroup Inc., Simplex Trading LLC, and Cutler Group LLC CA. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Beam Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 13,130,000 shares, an increase of 0.5% from the previous total of 13,060,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Beam Therapeutics: Recursion Pharmaceuticals, Inc. (17.61%), Arcellx, Inc. (18.85%), Vericel Co. (11.76%), SpringWorks Therapeutics, Inc. (23.22%), BioCryst Pharmaceuticals, Inc. (21.80%), Iovance Biotherapeutics, Inc. (14.72%), Immunocore Holdings plc (6.24%), Vir Biotechnology, Inc. (5.35%), Twist Bioscience Co. (24.70%), ProKidney Corp. (37.01%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.69 billion), Canadian Natural Resources Limited ($3.67 billion), T-Mobile US, Inc. ($3.56 billion), Suncor Energy Inc. ($3.20 billion), Occidental Petroleum Co. ($3.19 billion), Celsius Holdings, Inc. ($2.09 billion), Tractor Supply ($2.08 billion), Moderna, Inc. ($2.04 billion), Royal Caribbean Cruises Ltd. ($2.00 billion), and Rivian Automotive, Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling BEAM is an investing strategy that aims to generate trading profit from Beam Therapeutics as its price is falling. BEAM shares are trading up $0.59 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Beam Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BEAM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BEAM, twice per month. The most recent reporting period available is August, 31 2023.